Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Panel To Determine Whether Abraxane Needs Randomized Trial In Adjuvant Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The committee will consider if previous studies of Bristol’s Taxol, which has the same active ingredient as Abraxane, are sufficient to support approval via the 505(b)(2) pathway.

You may also be interested in...



Abraxane Randomized Trial Needed For Adjuvant Breast Cancer, Panel Says

ODAC votes in favor of Abraxis conducting an additional clinical trial to extend Abraxane’s indication from metastatic breast cancer into the adjuvant setting during a Sept. 7 meeting.

Abraxane Randomized Trial Needed For Adjuvant Breast Cancer, Panel Says

ODAC votes in favor of Abraxis conducting an additional clinical trial to extend Abraxane’s indication from metastatic breast cancer into the adjuvant setting during a Sept. 7 meeting.

ODAC To Review Pfizer’s Fragmin, Genta’s Genasense, Abraxis Bioscience’s Abraxane

The three products will be reviewed by the FDA advisory committee Sept. 6-7.

Topics

UsernamePublicRestriction

Register

PS064968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel